PE20191818A1 - Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol - Google Patents
Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3olInfo
- Publication number
- PE20191818A1 PE20191818A1 PE2019002024A PE2019002024A PE20191818A1 PE 20191818 A1 PE20191818 A1 PE 20191818A1 PE 2019002024 A PE2019002024 A PE 2019002024A PE 2019002024 A PE2019002024 A PE 2019002024A PE 20191818 A1 PE20191818 A1 PE 20191818A1
- Authority
- PE
- Peru
- Prior art keywords
- iodophenyl
- azetidin
- difluoro
- fluoro
- carbonyl
- Prior art date
Links
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 title 1
- -1 {3,4-DIFLUORO-2 - [(2-FLUORO-4-IODOPHENYL) AMINO] PHENYL} CARBONYL Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 abstract 1
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- BSMCAPRUBJMWDF-KRWDZBQOSA-N cobimetinib Chemical compound C1C(O)([C@H]2NCCCC2)CN1C(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F BSMCAPRUBJMWDF-KRWDZBQOSA-N 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261713104P | 2012-10-12 | 2012-10-12 | |
| PCT/US2013/064866 WO2014059422A1 (en) | 2012-10-12 | 2013-10-14 | Novel process for making compounds for use in the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191818A1 true PE20191818A1 (es) | 2019-12-27 |
Family
ID=49474740
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019002024A PE20191818A1 (es) | 2012-10-12 | 2013-10-14 | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol |
| PE2015000485A PE20151494A1 (es) | 2012-10-12 | 2013-10-14 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000485A PE20151494A1 (es) | 2012-10-12 | 2013-10-14 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
| PE2019001563A PE20200387A1 (es) | 2012-10-12 | 2019-08-08 | Proceso novedoso para la elaboracion de compuestos para su uso en el tratamiento del cancer |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US9771347B2 (OSRAM) |
| EP (1) | EP2909188B1 (OSRAM) |
| JP (2) | JP6300042B2 (OSRAM) |
| KR (1) | KR102204520B1 (OSRAM) |
| CN (2) | CN108948043B (OSRAM) |
| AU (1) | AU2013328929B2 (OSRAM) |
| BR (1) | BR112015008113B1 (OSRAM) |
| CA (1) | CA2889466C (OSRAM) |
| CL (1) | CL2015000926A1 (OSRAM) |
| CR (2) | CR20200237A (OSRAM) |
| EA (1) | EA030613B1 (OSRAM) |
| ES (1) | ES2671502T3 (OSRAM) |
| GE (1) | GEP201706690B (OSRAM) |
| HK (1) | HK1213567A1 (OSRAM) |
| HR (1) | HRP20180670T1 (OSRAM) |
| IL (1) | IL238116B (OSRAM) |
| IN (1) | IN2015DN03928A (OSRAM) |
| MA (1) | MA38085B1 (OSRAM) |
| MX (2) | MX372708B (OSRAM) |
| MY (1) | MY186549A (OSRAM) |
| NZ (1) | NZ706723A (OSRAM) |
| PE (3) | PE20191818A1 (OSRAM) |
| PH (1) | PH12015500785A1 (OSRAM) |
| PL (1) | PL2909188T3 (OSRAM) |
| SA (1) | SA515360271B1 (OSRAM) |
| SG (1) | SG11201502795VA (OSRAM) |
| SI (1) | SI2909188T1 (OSRAM) |
| TR (1) | TR201807861T4 (OSRAM) |
| UA (1) | UA115455C2 (OSRAM) |
| WO (1) | WO2014059422A1 (OSRAM) |
| ZA (1) | ZA201502349B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEP201706690B (en) | 2012-10-12 | 2017-06-26 | Exelixis Inc | Novel process for making compounds for use in treatment of cancer |
| US9532987B2 (en) | 2013-09-05 | 2017-01-03 | Genentech, Inc. | Use of a combination of a MEK inhibitor and an ERK inhibitor for treatment of hyperproliferative diseases |
| IL256299B2 (en) | 2015-06-30 | 2023-11-01 | Genentech Inc | Immediate-release tablets containing a drug and processes for creating the tablets |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
| CN105330643B (zh) * | 2015-12-09 | 2017-12-05 | 苏州明锐医药科技有限公司 | 卡比替尼的制备方法 |
| CN106045969B (zh) * | 2016-05-27 | 2019-04-12 | 湖南欧亚药业有限公司 | 一种卡比替尼的合成方法 |
| CN109689102A (zh) | 2016-08-12 | 2019-04-26 | 基因泰克公司 | Mek抑制剂,pd-1轴抑制剂,和vegf抑制剂的组合疗法 |
| CA3038671A1 (en) | 2016-09-29 | 2018-04-05 | Genentech, Inc. | Combination therapy with a mek inhibitor, a pd-1 axis inhibitor, and a taxane |
| WO2020187674A1 (en) | 2019-03-15 | 2020-09-24 | Sandoz Ag | Crystalline (s)-[3,4-difluoro-2-(2-fluoro-4-iodophenylamino)phenyl][3-hydroxy-3-(piperidin-2-yl)azetidin-1-yl]methanone hemisuccinate |
| US20240173329A1 (en) | 2021-03-09 | 2024-05-30 | Genentech, Inc. | Belvarafenib for use in treatment of brain cancers |
| CN117561062A (zh) | 2021-04-06 | 2024-02-13 | 基因泰克公司 | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1563587A (en) * | 1924-09-20 | 1925-12-01 | Raney Murray | Method of preparing catalytic material |
| US1628190A (en) * | 1926-05-14 | 1927-05-10 | Raney Murray | Method of producing finely-divided nickel |
| US1915473A (en) * | 1930-12-31 | 1933-06-27 | Raney Murray | Method of preparing catalytic material |
| US4510139A (en) | 1984-01-06 | 1985-04-09 | Sterling Drug Inc. | Substituted aminobenzamides and their use as agents which inhibit lipoxygenase activity |
| US5155110A (en) | 1987-10-27 | 1992-10-13 | Warner-Lambert Company | Fenamic acid hydroxamate derivatives having cyclooxygenase and 5-lipoxygenase inhibition |
| EP0754684A4 (en) | 1994-04-01 | 1998-05-13 | Shionogi & Co | OXIME DERIVATIVES AND BACTERICIDE CONTAINING IT AS ACTIVE INGREDIENTS |
| AU6966696A (en) | 1995-10-05 | 1997-04-28 | Warner-Lambert Company | Method for treating and preventing inflammation and atherosclerosis |
| AU5610398A (en) | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| EP0993437B1 (en) * | 1997-07-01 | 2006-11-08 | Warner-Lambert Company Llc | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as mek inhibitors |
| US6310060B1 (en) * | 1998-06-24 | 2001-10-30 | Warner-Lambert Company | 2-(4-bromo or 4-iodo phenylamino) benzoic acid derivatives and their use as MEK inhibitors |
| EP0993439B1 (en) | 1997-07-01 | 2004-09-29 | Warner-Lambert Company LLC | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| US6974878B2 (en) | 2001-03-21 | 2005-12-13 | Symyx Technologies, Inc. | Catalyst ligands, catalytic metal complexes and processes using same |
| HUP0104607A3 (en) | 1998-12-15 | 2002-12-28 | Warner Lambert Co | Use of a mek inhibitor for preventing transplant rejection |
| WO2000035436A2 (en) | 1998-12-16 | 2000-06-22 | Warner-Lambert Company | Treatment of arthritis with mek inhibitors |
| TR200101871T2 (tr) | 1998-12-22 | 2001-10-22 | Warner-Lambert Company | Kombine kemoterapi |
| KR20000047461A (ko) | 1998-12-29 | 2000-07-25 | 성재갑 | 트롬빈 억제제 |
| US6696440B1 (en) | 1999-01-07 | 2004-02-24 | Warner-Lambert Company | Treatment of asthma with MEK inhibitors |
| IL144103A0 (en) | 1999-01-07 | 2002-05-23 | Warner Lambert Co | Antiviral method using mek inhibitors |
| BR9916857A (pt) | 1999-01-13 | 2001-12-04 | Warner Lambert Co | 4 heteroaril diarilaminas |
| EP1144394B1 (en) | 1999-01-13 | 2005-08-24 | Warner-Lambert Company LLC | 1-heterocycle substituted diarylamines |
| CA2348236A1 (en) | 1999-01-13 | 2000-07-20 | Stephen Douglas Barrett | 4-arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective mek inhibitors |
| HUP0105113A3 (en) | 1999-01-13 | 2004-11-29 | Warner Lambert Co | Benzoheterocycles and their use as mek inhibitors and pharmaceutical compositions containing the compounds |
| DE69928286T2 (de) | 1999-01-13 | 2006-07-13 | Warner-Lambert Co. Llc | Benzenesulfonamid-derivative und ihre verwendung als mek-inhibitoren |
| PL352705A1 (en) | 1999-07-16 | 2003-09-08 | Warner-Lambert Company | Method for treating chronic pain using mek inhibitors |
| EP1202726A2 (en) | 1999-07-16 | 2002-05-08 | Warner-Lambert Company Llc | Method for treating chronic pain using mek inhibitors |
| CN1358094A (zh) | 1999-07-16 | 2002-07-10 | 沃尼尔·朗伯公司 | 用mek抑制剂治疗慢性疼痛的方法 |
| ES2208364T3 (es) | 1999-07-16 | 2004-06-16 | Warner-Lambert Company Llc | Procedimiento para tratar dolor cronico usando inhibidores de mek. |
| KR20020047175A (ko) | 1999-09-17 | 2002-06-21 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | Ｘａ 인자의 억제제 |
| JP2003527379A (ja) | 2000-03-15 | 2003-09-16 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｍｅｘ阻害物質としての５−アミド置換ジアリールアミン類 |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| DK1301472T3 (da) | 2000-07-19 | 2014-04-07 | Warner Lambert Co | Oxygenerede estere af 4-iod-phenylamino-benzhydroxamsyrer |
| IL154507A0 (en) * | 2000-08-25 | 2003-09-17 | Warner Lambert Co | Process for making n-aryl-anthranilic acids and their derivatives |
| US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| IL149462A0 (en) | 2001-05-09 | 2002-11-10 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US20040039208A1 (en) * | 2001-07-20 | 2004-02-26 | Chen Michael Huai Gu | Process for making n-aryl-anthranilic acids and their derivatives |
| DE10141266A1 (de) | 2001-08-21 | 2003-03-06 | Syntec Ges Fuer Chemie Und Tec | Elektrolumineszierende Derivate der 2,5-Diamino-terephthalsäure und deren Verwendung in organischen Leuchtdioden |
| US7085492B2 (en) | 2001-08-27 | 2006-08-01 | Ibsen Photonics A/S | Wavelength division multiplexed device |
| HUP0401967A2 (hu) | 2001-10-31 | 2005-01-28 | Pfizer Products Inc. | Nikotinsav-acetilkolin-receptor-agonisták alkalmazása nyugtalan láb szindróma kezelésére alkalmas gyógyszerkészítmények előállítására |
| DOP2003000556A (es) | 2002-01-23 | 2003-10-31 | Warner Lambert Co | Esteres hidroxamato de acido n-(4-fenil-sustituido)-antranilico. |
| JP2005515253A (ja) | 2002-01-23 | 2005-05-26 | ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー | Ｎ−（４−置換フェニル）−アントラニル酸ヒドロキサメートエステル |
| CN101633645B (zh) | 2002-03-13 | 2011-06-22 | 阵列生物制药公司 | 作为mek抑制剂的n3烷基化苯并咪唑衍生物 |
| RU2300528C2 (ru) | 2002-03-13 | 2007-06-10 | Эррэй Биофарма, Инк. | N3-алкилированные бензимидазольные производные в качестве ингибиторов мек |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| WO2003103590A2 (en) | 2002-06-11 | 2003-12-18 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
| GB0214268D0 (en) | 2002-06-20 | 2002-07-31 | Celltech R&D Ltd | Chemical compounds |
| WO2004004644A2 (en) | 2002-07-05 | 2004-01-15 | Beth Israel Deaconess Medical Center | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| US20050004186A1 (en) | 2002-12-20 | 2005-01-06 | Pfizer Inc | MEK inhibiting compounds |
| EP1606283B1 (en) | 2003-03-03 | 2008-10-08 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TW200505834A (en) | 2003-03-18 | 2005-02-16 | Sankyo Co | Sulfamide derivative and the pharmaceutical composition thereof |
| JP2005162727A (ja) | 2003-03-18 | 2005-06-23 | Sankyo Co Ltd | スルファミド誘導体及びその医薬組成物 |
| GB0308185D0 (en) | 2003-04-09 | 2003-05-14 | Smithkline Beecham Corp | Novel compounds |
| KR20060021905A (ko) | 2003-06-20 | 2006-03-08 | 셀테크 알앤디 리미티드 | 키나아제 억제제로서의 티에노피리돈 유도체 |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| US20050049276A1 (en) | 2003-07-23 | 2005-03-03 | Warner-Lambert Company, Llc | Imidazopyridines and triazolopyridines |
| EP1651214B1 (en) | 2003-07-24 | 2009-09-16 | Warner-Lambert Company LLC | Benzimidazole derivatives as mek inhibitors |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| WO2005028426A1 (ja) | 2003-09-19 | 2005-03-31 | Chugai Seiyaku Kabushiki Kaisha | 新規４−フェニルアミノ−ベンズアルドオキシム誘導体並びにそのmek阻害剤としての使用 |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| HRP20110105T4 (hr) | 2003-11-19 | 2013-03-31 | Array Biopharma, Inc. | Mek heterocikliäśki inhibitori |
| WO2005058887A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
| MY144232A (en) | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| PL1802579T3 (pl) * | 2004-10-20 | 2014-04-30 | Merck Serono Sa | Pochodne 3-aryloaminopirydynowe |
| WO2006061712A2 (en) | 2004-12-10 | 2006-06-15 | Pfizer Inc. | Use of mek inhibitors in treating abnormal cell growth |
| US7547782B2 (en) | 2005-09-30 | 2009-06-16 | Bristol-Myers Squibb Company | Met kinase inhibitors |
| PL1934174T3 (pl) * | 2005-10-07 | 2011-09-30 | Exelixis Inc | Azetydyny jako inhibitory w leczeniu chorób proliferacyjnych |
| ATE539752T1 (de) | 2006-08-16 | 2012-01-15 | Exelixis Inc | Verwendung von pi3k- und mek-modulatoren bei der krebsbehandlung |
| CN101605540A (zh) * | 2006-12-14 | 2009-12-16 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
| GEP201706690B (en) | 2012-10-12 | 2017-06-26 | Exelixis Inc | Novel process for making compounds for use in treatment of cancer |
| CN105992755B (zh) | 2014-02-07 | 2018-07-13 | 住友化学株式会社 | (r)-1,1,3-三甲基-4-氨基茚满的制造方法 |
| AR105483A1 (es) | 2015-06-30 | 2017-10-11 | Exelixis Inc | Sal de fumarato cristalina de (s)-[3,4-difluoro-2-(2-fluoro-4-yodofenilamino)fenil][3-hidroxi-3-(piperidin-2-il)azetidin-1-il]-metanona |
-
2013
- 2013-10-14 GE GEAP201313824A patent/GEP201706690B/en unknown
- 2013-10-14 AU AU2013328929A patent/AU2013328929B2/en active Active
- 2013-10-14 CR CR20200237A patent/CR20200237A/es unknown
- 2013-10-14 HR HRP20180670TT patent/HRP20180670T1/hr unknown
- 2013-10-14 TR TR2018/07861T patent/TR201807861T4/tr unknown
- 2013-10-14 MX MX2015004660A patent/MX372708B/es active IP Right Grant
- 2013-10-14 MY MYPI2015000897A patent/MY186549A/en unknown
- 2013-10-14 BR BR112015008113-4A patent/BR112015008113B1/pt active IP Right Grant
- 2013-10-14 PE PE2019002024A patent/PE20191818A1/es unknown
- 2013-10-14 MA MA38085A patent/MA38085B1/fr unknown
- 2013-10-14 HK HK16101572.6A patent/HK1213567A1/zh unknown
- 2013-10-14 KR KR1020157012066A patent/KR102204520B1/ko active Active
- 2013-10-14 SG SG11201502795VA patent/SG11201502795VA/en unknown
- 2013-10-14 EA EA201590700A patent/EA030613B1/ru not_active IP Right Cessation
- 2013-10-14 PL PL13780303T patent/PL2909188T3/pl unknown
- 2013-10-14 ES ES13780303.7T patent/ES2671502T3/es active Active
- 2013-10-14 UA UAA201504532A patent/UA115455C2/uk unknown
- 2013-10-14 CA CA2889466A patent/CA2889466C/en active Active
- 2013-10-14 WO PCT/US2013/064866 patent/WO2014059422A1/en not_active Ceased
- 2013-10-14 CN CN201810758236.XA patent/CN108948043B/zh active Active
- 2013-10-14 JP JP2015536988A patent/JP6300042B2/ja active Active
- 2013-10-14 PE PE2015000485A patent/PE20151494A1/es active IP Right Grant
- 2013-10-14 CN CN201380064338.7A patent/CN104837826B/zh active Active
- 2013-10-14 NZ NZ706723A patent/NZ706723A/en unknown
- 2013-10-14 EP EP13780303.7A patent/EP2909188B1/en active Active
- 2013-10-14 SI SI201331045T patent/SI2909188T1/en unknown
- 2013-10-14 IN IN3928DEN2015 patent/IN2015DN03928A/en unknown
-
2015
- 2015-04-02 IL IL238116A patent/IL238116B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/02349A patent/ZA201502349B/en unknown
- 2015-04-08 PH PH12015500785A patent/PH12015500785A1/en unknown
- 2015-04-10 MX MX2020005533A patent/MX2020005533A/es unknown
- 2015-04-12 SA SA515360271A patent/SA515360271B1/ar unknown
- 2015-04-13 CL CL2015000926A patent/CL2015000926A1/es unknown
- 2015-04-13 US US14/684,826 patent/US9771347B2/en active Active
- 2015-05-11 CR CR20150245A patent/CR20150245A/es unknown
-
2017
- 2017-08-25 US US15/686,333 patent/US10239858B2/en active Active
- 2017-12-06 JP JP2017234208A patent/JP2018052973A/ja not_active Withdrawn
-
2019
- 2019-02-08 US US16/271,215 patent/US10793541B2/en active Active
- 2019-08-08 PE PE2019001563A patent/PE20200387A1/es unknown
-
2020
- 2020-08-26 US US17/003,570 patent/US11414396B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191818A1 (es) | Proceso para la elaboracion de 1-({3,4-difluoro-2-[(2-fluoro-4-yodofenil)amino]fenil}carbonil)-3-[(2s)-piperidin-2-il]azetidin-3ol | |
| CR20150078A (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| TN2014000122A1 (en) | 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases | |
| MX361499B (es) | Baricitinib deuterado. | |
| PH12015501316A1 (en) | Heterocyclic compound | |
| NZ710444A (en) | Compositions and methods for treating neurodegenerative diseases and cardiomyopathy | |
| MY207356A (en) | Nrf2 regulators | |
| MY164776A (en) | Heterocyclic compound | |
| MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
| IN2015DN00598A (OSRAM) | ||
| TN2014000095A1 (en) | Pharmaceutical compositions | |
| EA201590951A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
| EA201590954A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| UY33557A (es) | Inhibidores de oxadiazol de la produccion de leucotrieno | |
| EA201590949A1 (ru) | Дигидропиразольные модуляторы gpr40 | |
| IN2014DN07224A (OSRAM) | ||
| BR112015015368A2 (pt) | composições de absorventes de dejetos de animais revestidas debaixa densidade | |
| MX2014002832A (es) | Nuevas imidazol-aminas como moduladores de la actividad de cinasas. | |
| SG10201805896SA (en) | PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS | |
| NI201200195A (es) | Procedimiento de preparación de la sal de l - arginina de perindoprilo | |
| EA201691999A1 (ru) | Новые сульфониламинобензамидные соединения | |
| IN2014DN07954A (OSRAM) | ||
| IN2014DN07220A (OSRAM) | ||
| MX2013014488A (es) | Metodos y composiciones para tratar el cancer cerebral. |